Fractyl Health Faces Investor Scrutiny After Study Disclosures and Stock Fall
Fractyl Health, Inc. (NASDAQ:GUTS) is under investor scrutiny following disclosures regarding its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after stopping GLP-1 therapy. Data showed Revita-treated patients regained 4.5% of their weight versus 7.5% for the sham group, while management noted the cohort lacked statistical power for efficacy analysis.
Management later disclosed that higher-than-expected weight regain at a single trial site significantly impacted overall results, attributing the issue to weaker diet and lifestyle counseling. The news triggered immediate market reaction, sending shares down 68.03% to $0.585 on January 29, 2026. Following an analyst downgrade from Morgan Stanley lowering its target price from $8.00 to $2.00, the stock fell another 21.37% the following day to close at $0.46.
With shares currently trading down 10.97% today at $1.38, investors continue to monitor corporate governance and legal developments surrounding the trial disclosures and subsequent financial loss.
Key points
- Fractyl Health reported six-month REMAIN-1 trial data showing a 4.5% weight regain for Revita patients compared to 7.5% for the sham group.
- Management revealed a single study site with higher weight regain materially distorted overall trial results due to inconsistent lifestyle counseling.
- Morgan Stanley downgraded Fractyl stock and reduced its price target from $8.00 to $2.00 following the announcement.
- Fractyl Health shares dropped over 68% on January 29, 2026, and currently trade at $1.38 after falling 10.97% today.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Fractyl Health stock drop in January 2026?
Fractyl Health shares fell 68.03% on January 29, 2026, after reporting trial data for Revita where higher-than-expected weight regain at a single study site materially impacted results. Management noted the trial cohort was not powered for efficacy analysis.
What were the results of Fractyl Health's REMAIN-1 study?
In the six-month REMAIN-1 cohort, Revita-treated patients experienced a 4.5% weight regain after stopping GLP-1 therapy, compared to 7.5% in the sham-treatment group. However, results were affected by variability at one trial site.
What is the current stock price and ticker for Fractyl Health?
Fractyl Health trades on the NASDAQ under the ticker GUTS. The stock is currently priced at $1.38 per share, down 10.97% today.